Congress Asset Management’s Tango Therapeutics TNGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.9M Buy
478,454
+97,708
+26% +$2.54M 0.08% 207
2026
Q2
$11.9M Buy
380,746
+39,385
+12% +$974K 0.07% 203
2026
Q1
$7.14M Buy
341,361
+106,733
+45% +$1.49M 0.05% 232
2025
Q4
$2.08M Buy
234,628
+6,508
+3% +$56.1K 0.01% 279
2025
Q3
$1.92M Buy
228,120
+926
+0.4% +$6.27K 0.01% 286
2025
Q2
$1.16M Sell
227,194
-167
-0.1% -$413 0.01% 311
2025
Q1
$311K Sell
227,361
-628
-0.3% -$1.54K ﹤0.01% 348
2024
Q4
$704K Buy
227,989
+18,919
+9% +$87.8K ﹤0.01% 332
2024
Q3
$1.61M Sell
209,070
-2,100
-1% -$20K 0.01% 287
2024
Q2
$1.81M Buy
+211,170
New +$1.63M 0.01% 281

Other funds holding TNGX

Congress Asset Management's TNGX Position: Q3 2026 in Review

Congress Asset Management increased its Tango Therapeutics (TNGX) stake by 26% in Q3 2026, buying an estimated $2.54M and bringing the position to 478,454 shares worth $11.9M. The position accounts for 0.08% of the portfolio, ranked #207.

Congress Asset Management first reported a position in TNGX in Q2 2024 and has held it in 10 quarters since. 3 funds tracked by Wall St. Rank hold TNGX as of Q3 2026.

  • Congress Asset Management held 478,454 shares of Tango Therapeutics worth $11.9M as of Q3 2026.
  • Congress Asset Management bought 97,708 Tango Therapeutics shares in Q3 2026, an estimated $2.54M.
  • Tango Therapeutics made up 0.08% of Congress Asset Management's portfolio in Q3 2026, its #207 holding.
  • Congress Asset Management first reported a position in Tango Therapeutics in Q2 2024 and has held it in 10 quarters since.
  • 3 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2026.

Based on Congress Asset Management's 13F filing for Q3 2026, filed 6 Oct 2026.